Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies - Concepedia

Concepedia

Publication | Closed Access

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

402

Citations

15

References

2005

Year

Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Stacie Richardson, Robert D. Willim, Barbara MacGregor‐Cortelli, Tracey Curly, Craig H. Moskowitz, Carol S. Portlock, Steven M. Horwitz,

Journal of Clinical Oncology

Abstract

These results suggest that SAHA has activity in hematologic malignancies including HD and select subtypes of non-Hodgkin's lymphoma.

References

	Year	Citations

Page 1